Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This chapter reviews trichoscopic-pathologic correlations in Frontal Fibrosing Alopecia and reports no new clinical results; the authors discuss genetics, clinical patterns, and unusual variants associated with this condition.

This study found that the Severity of Alopecia Tool score does not predict the quality of life in patients with alopecia areata, suggesting patient-reported outcomes better reflect the impact on life quality.

This study identified multiple factors affecting the severity of alopecia areata, suggesting they could inform a tool for measuring disease impact and guide treatment selection.

This case report presents three sisters with familial frontal fibrosing alopecia, making it the 25th documented familial case, with treatment results observed in one sister.

This consensus report outlines Brazilian dermatologists' recommendations for treating alopecia areata, highlighting intralesional corticosteroids for localized cases and systemic therapy for extensive, active disease, along with monitoring side effects.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.

This case report presents a 14-year-old girl with both type I diabetes and monilethrix, detailing her symptoms and treatment with topical minoxidil, while exploring a possible genetic link between the conditions.

In this case report, an 8-year-old with severe alopecia areata and atopic dermatitis experienced significant hair regrowth and improved dermatitis symptoms after treatment with dupilumab followed by baricitinib, with no major side effects observed.

This study suggests that lichen planopilaris should be considered as a potential diagnosis in African American women with scarring alopecia, often displaying an "arrowhead" distribution pattern, which may guide treatment strategies.

This case report describes a patient with alopecia universalis who had an excellent and persistent response to oral tofacitinib treatment after one year.

The authors report that a 62-year-old woman with invasive conjunctival squamous cell carcinoma experienced complete remission two years after combining cemiplimab, retinoic acid, and IFNα-2b treatments, highlighting potential utility despite limited availability of IFNα-2b.

In this study of a Colombian sample, the researchers found that while sex, alopecia location, and symptoms aligned with global reports, age at presentation, tobacco use, and use of wigs and dyes were different from those noted in other countries.

This case report describes three pediatric cases of frontal fibrosing alopecia, a condition typically seen in postmenopausal women, including a unique instance involving female twins.

This report discusses a series of patients with frontal fibrosing alopecia experiencing increased scalp sweating, which the authors hypothesize may be related to local skin inflammation affecting sweat gland activity.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This report describes two cases of folliculotropic mycosis fungoides with syringotropism, highlighting indolent progression despite the disease's typically aggressive nature, suggesting aggressive treatment might not be necessary.

This retrospective case series reported that pediatric patients with alopecia totalis and subtotalis experienced significant hair regrowth after treatment with the JAK inhibitor upadacitinib, with mild acne as the most common side effect; however, larger studies are needed to establish its efficacy and safety conclusively.

This review discusses the possible link between cosmeceuticals and frontal fibrosing alopecia but reports no conclusive findings; the authors stress further research on environmental triggers is needed.

In this retrospective study, baricitinib effectively improved alopecia areata in 78.7% of patients by the end of treatment, with significant hair regrowth observed, particularly in those with disease duration of four years or less, and showed no serious adverse events.

In this case report, a 40-year-old male with alopecia universalis and twenty-nail dystrophy showed significant nail improvement and partial hair regrowth after six months of baricitinib treatment, improving his quality of life.

This study found that treatment with baricitinib 4 mg over 52 weeks led to clinically meaningful regrowth of eyebrows and eyelashes in patients with alopecia areata, even without complete scalp hair regrowth.

This review discusses treatments for frontal fibrosing alopecia and lichen planopilaris, noting that systemic 5-alpha reductase inhibitors are most effective for stabilization and potential hair regrowth, but reports no new clinical results.

In this study, researchers characterized the clinical features of ophiasis, an uncommon type of alopecia areata, and proposed a new subtype classification that may help predict treatment response and guide management, noting that ophiasis generally has a chronic and refractory nature.

This review discusses the genetic origins of autosomal recessive woolly hair with hypotrichosis and reports no clinical results; it highlights the link to homozygous variants in the K25 keratin gene.

This study examined the clinicopathologic and trichoscopic characteristics of keratosis follicularis spinulosa decalvans and identified terminal hair involvement and follicular hyperkeratosis as key diagnostic features.

In this study, patients with frontal fibrosing alopecia showed more actinic damage than control subjects, suggesting sunscreen use by these patients may be a consequence rather than a cause of the condition.

This study found that dermatoscopy can quickly and non-invasively detect facial vellus hair involvement in patients with alopecia frontal fibrosante, occurring frequently and associated with specific facial lesions.

This case report indicates that retinoblastoma can occur in a microphthalmic eye and recommends using multiple imaging techniques due to potential differences in calcification visibility.

This study found that intralesional corticosteroids remain the preferred treatment for alopecia areata with limited involvement, while platelet-rich plasma showed promise, particularly in children and extensive cases.